Our mission is to reduce the cost of biomanufacturing by increasing drug yields. We strive to offer end-to-end CLD services with proprietary, state-of-the-art technology proven to find the best cell line for a given biomanufacturing process. With our platform, we aim to make biopharmaceutical therapies more accessible and affordable, all while accelerating new drugs’ movement from discovery to delivery.

We envision a CLD process that is faster, easier, and less expensive than existing methods—all while screening thousands of times more cells for desirable characteristics than the status quo. Biolinco will realize its mission and vision by proving its platform through the development of a biosimilar-producing cell line.